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1. Introduction 
The skin and its appendages protect the body from water loss, chemical and physical 
damages, UV-radiation and infection by pathogenic as well as non-pathogenic microbes. 
The protective function of both, the physical and the chemical barrier, is provided from 
epidermal keratinocytes, which are continuously dividing in the stratum basale and 
differentiating towards the surface (Candi et al. 2005). Cells of the uppermost living 
epidermis layer, the stratum granulosum, are loosing their nuclei and other organelles at 
the transition zone to the stratum corneum (SC), forming now flattened polyhedrons, 
called corneocytes.  These corneocytes contain instead of a cell membrane the cornified 
envelope (CE) consisting of structural proteins, which are crosslinked by glutaminases 
(Candi et al. 2005). The intercellular space of the corneocytes is filled with lamellar body-
derived lipids, which make the SC more hydrophobous. This mechanism protects skin 
from water loss and other insults. 
Finally, in a tightly regulated process termed desquamation that abolishes the cohesion 
between corneocytes, these cells are shed into the environment by proteolysis of 
corneodesmosomal proteins. The formation of stratified epithelia requires a specific 
differentiation program, which includes a timely and spatially well coordinated 
proteolytic system to detach the corneocytes from each other without any disturbance of 
the barrier function. During the last years it became evident that this proteolytic balance is 
not only important for the physical barrier function of the skin but is also paving the way 
for immunological responses. In this chapter we want to look at the various proteases in 
the epidermis, their inhibitors and how they might contribute to the pathogenesis of 
atopic dermatitis (AD).  
2. Proteases 
A number of different proteases and their inhibitors have been involved in the 
desquamation process and to contribute to the skin’s barrier function. On the basis of the 
catalytic domain, proteases are classified into aspartate-, cysteine-, glutamate-, metallo-, 
serine- and threonine proteases. Particularly serine proteases (SP) have a prominent role in 
epidermal permeability barrier homeostasis, as acute barrier disruption increases SP-activity 
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in skin and inhibition by topical SP-inhibitors accelerated recovery of barrier function after 
acute abrogation (Hachem et al. 2006). 
2.1 Cysteine- and aspartate-proteases 
Cysteine peptidases represent phylogenetically ubiquitous enzymes, which can be classified 
into clans of independent proteins (based on the structural organization of the active site). 
Two of the major clans in mammal genomes are the “CA” clan, where members share an 
evolutionary and structural history with papain, and the “CB” clan, which includes the 
caspases and the legumains. 
One of the most skin-relevant caspases is the cysteinyl-aspartate protease caspase-14 
(Demerjian et al. 2008). In contrast to other ubiquitously expressed members of the caspase 
family, caspase-14 is rather specifically expressed within the epidermis, where it is of high 
importance in the formation of the physical skin barrier. It is expressed in keratinocytes of 
the uppermost stratum granulosum, where it was found to be associated with the nucleus, 
the keratohyalin granules and the desmosomes. Although its localization suggested a role 
for nuclear degradation during cornification, in caspase-14-deficient mice nuclear 
degradation was not affected. The observation that caspase-14 has only been found in 
terrestrial mammals but not in birds or reptiles and that profilaggrin is a direct substrate of 
caspase 14, suggests that it is important for formation of a soft stratum corneum. This could 
indicate a co-evolution of a soft SC and the caspase-14 gene (Denecker et al. 2007). Caspase-
14 is produced as procaspase within the stratum granulosum, where it maturates in 
cornifying epithelia. Although it is not clear how it maturates, most likely a serine protease 
with elastase-like properties could be involved (Denecker et al. 2008). Thus, caspase-14 
seems to be involved in the correct processing of profilaggrin, preceding its degradation into 
hygroscopic amino acids as well as the formation of UVB-protective compounds. 
Another skin cysteine peptidase is cathepsin C, which represents a lysosomal cysteine 
peptidase of the papain family CIA, which is important for intracellular degradation and 
which has a role in the activation of serine proteases in immune cells (Rao et al. 1997). 
Cathepsin C knockout mice indicated that activation and processing of granzymes A and B, 
which are important for T-cell-mediated cell-killing, depends on cathepsin C (Pham and Ley 
1999). Interestingly, Cathepsin C deficiency in humans leads to a dramatic reduction of both, 
levels and activities of the neutrophil serine proteases elastase, protease-3 and cathepsin G 
(Pham et al. 2004), which will be described below. 
Cathepsin D represents the main aspartic protease of endolysosomes. It is active at the 
physiological acidic pH of healthy skin and is of relevance in the desquamation process 
(Horikoshi et al. 1999). Cathepsin D knockout mice showed reduced levels of involucrin and 
loricrin and lower transglutaminase 1 activity, which indicates that cathepsin D contributes 
indirectly to the barrier function of human skin (Egberts et al. 2004).  
2.2 Serine proteases 
Serine proteases represent a family of enzymes which use a catalytic triad in the substrate-
binding pocket (Ser, His, Asp) to cleave peptide bonds. On the basis of their substrate 
specificity these proteases can be subdivided into trypsin-like enzymes (cleaves C-
terminally of Arg and Lys), chymotryptic enzymes (cleave behind aromatic or bulky, 
hydrophobic amino acids, and the elastase-like enzymes (cleave behind small or medium 
size non-polar amino acids. These enzymes play an important role in the terminal 
differentiation process and desquamation. 
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2.2.1 Matriptase and prostasin  
One of the most important players in epidermal barrier function is profilaggrin. It is 
processed at the stratum granulosum/stratum corneum interphase to filaggrin monomers. 
These are crosslinked to form macrofibrils and eventually “natural moisturing factors, 
NMFs), which are important for maintaining the hydration of the SC (reviewed in (Ovaere 
et al. 2009). The importance of profilaggrin proteolysis to maintain epidermal structure and 
hydration has been underscored by human genetic studies: These have shown that loss-of-
function mutations in profilaggrin cause ichthyosis vulgaris and are strongly predisposing 
to atopic dermatitis and asthma, possibly due to a disturbed epidermal barrier function, 
which allows entry of allergens and infectious agents (Sandilands et al. 2006). 
Major proteases required for initiating profilaggrin processing are the type II 
transmembrane serine protease matriptase and prostasin, a glycosylphosphatidylinositol-
anchored membrane serine protease. There is now evidence that the autoactivating 
protease matriptase acts upstream of prostasin in a zymogen activation cascade that 
regulates terminal epidermal differentiation and is required for prostasin zymogen 
activation (Netzel-Arnett et al. 2006). A reduced matriptase expression was shown to be 
associated with incomplete terminal differentiation of epidermis, epidermal appendages, 
and oral epithelium (Bugge et al. 2007).  Matriptase gene mutations lead to ichthyosis as 
recently reported (Alef et al. 2008).  Matriptase is immediately activated by exposure to an 
acidic pH, as it occurs in skin, suggesting that matriptase activation may be a direct 
response to proton exposure (Tseng et al. 2010). Recent evidence showed that during 
epidermal differentiation, the matriptase-prostasin proteolytic cascade is tightly regulated 
by two mechanisms, either by prostasin activation temporally coupled to matriptase 
autoactivation or by the hepatocyte growth factor activator-inhibitor-1(HAI-1), which is 
rapidly inhibiting not only active matriptase but also active prostasin, resulting in an 
extremely brief window of opportunity for both active matriptase and active prostasin to 
act on their substrates (Chen et al. 2010). So far these two membrane-bound proteases are 
thought to be mainly involved in skin homeostasis. However, the ability of matriptase to 
activate Kallikrein-related proteases in the skin points to a regulatory role of matriptase in 
inflammatory skin diseases (Sales et al. 2010).  
2.2.2 Kallikrein-related peptidases  
Kallikrein-related proteases (KLKs) are the largest family of tryptic and chymotryptic serine 
proteases, which are encoded by 15 genes on chromosome 19q13.4. In skin, KLKs are 
produced by keratinocytes of the stratum granulosum (SG), where they are released into 
interstices of the upper SG and lower SC. To date, SC serine protease activity is attributed to 
human tissue KLKs (Borgono et al. 2007). At least eight KLKs have been reported to be 
expressed in healthy skin, of which KLK5, KLK7, KLK8, and KLK14 seem to be the most 
important (reviewed in (Lundwall and Brattsand 2008)). Their putative function has been 
extensively studied (reviewed in (Eissa and Diamandis 2008; Lundwall and Brattsand 2008). 
A wealth of literature revealed proteolytic function of the two serine proteases, KLK5 and 
KLK7, in SC. These proteases, previously termed ‘stratum corneum tryptic enzyme, SCTE’ 
(KLK5) and ‘stratum corneum chymotryptic enzyme, SCCE’ (KLK7), have an important role 
in the desquamation process, as it was shown that serine protease inhibitors were able to 
inhibit corneocyte shedding from human plantar skin ex vivo (Lundstrom and Egelrud 
1988). Both enzymes are maximally expressed in the stratum granulosum, where they are 
released from lamellar bodies and located within stratum corneum interstices. Here they are 
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thought to form a proteolytic cascade in which KLK5 activates itself as well as KLK7 
(Ovaere et al. 2009). Once active, both enzymes are believed to digest in vivo 
corneodesmosin, DSG1 and desmocollin-1, as these substrates have been shown to be 
digested in vitro. There is now evidence that also other KLKs participate in desquamation: It 
was recently shown, that KLK14 is responsible for 50% of the total trypsin-like serine 
protease activity in the stratum corneum. Because KLK14 can activate and be activated by 
KLK5, it is very likely that it also participates in the cascade pathway.  
Apart from these three KLKs also KLK8 seems to be involved in a proteolytic activation 
cascade regulating skin desquamation: KLK8 is abundantly expressed and co-localized with 
other KLKs in human epidermis and sweat glands. It is also transported and exocytosed by 
lamellar bodies into the stratum granulosum/stratum corneum interface and thus may play 
a role in SC barrier functions. Very recent studies showed that recombinant KLK8 is 
optimally active at pH 8.5 suggesting that it plays a role in the upper stratum granulosum 
where the pH is rather neutral (Eissa et al. 2011). Active KLK8 has been found in SC extracts 
and in sweat, where until recently only KLK1 and kininase II were identified as active serine 
proteases. This raises its potential functional involvement in skin desquamation, although 
the physiological substrates need to be identified. 
2.3 Proteases of bacterial, fungal and parasite origin  
Apart from proteases produced by keratinocytes during differentiation and desquamation, 
the stratum corneum might also contain extracellular proteases originating from microbes 
and/or parasites residing at the skin surface. Bacterial proteases are often accessory proteins 
which are not fundamental for cell growth and division, but are considered to be virulence 
factors, which are often associated with mobile genetic elements such as plasmids, 
integrated phages and pathogenic islands. The clustering of bacterial protease genes in 
operons allows their coordinated expression, which in turn may imply a cooperation of the 
produced proteins (Wladyka and Pustelny 2008). 
Staphylococci produce a number of extracellular proteases, among them epidermolytic toxins, 
staphylococcal serine proteases like a glutamyl endopeptidase referred to as V8, a cysteine 
protease in S. aureus. Similar and other proteases are produced by skin-relevant bacteria, 
including commensal S. epidermidis, Streptococcus pyogenes, Pseudomonas aeruginosa and 
others (Wladyka and Pustelny 2008). Among the proteases, serine proteases, cysteine 
proteases and metalloproteases represent the most abundant bacterial proteases. These 
affect the host’s innate immune system in a bacterial species-specific manner by targeting 
phagocytes, cytokines and cytokine receptors, inflammatory signaling pathways, 
complement, contact activation as well as antimicrobial peptides (Potempa and Pike 2009). 
Apart from bacteria also fungi represent an important source of proteases. Upon fungal 
infections, which are mostly seen at mucosal surfaces, Candida albicans represents the most 
common fungal pathogen. Candida species are ubiquitous commensal yeasts that reside as 
part of the normal mucosa microflora without causing infections. Suitable predisposing 
conditions will let C. albicans change to a ‘pathogenic’stage, in which proteases represent 
major virulence factors. These are exclusively secreted aspartyl proteases (SAPs) (Naglik 
et al. 2004). It is believed that extracellular proteases of saprophytic microorganisms are 
primarily secreted to get nutrients from decomposition of complex materials. There is, 
however, strong evidence, that SAPs are also needed for invasion of the host, thereby 
interacting with several important host defense functions eventually causing 
inflammation (Naglik et al. 2004). 
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Proteolysis is also a vital element for survival of parasites, which enables them to digest 
resistant structural proteins. E. g. house dust mites (Dermatophagoides pteronyssinus and D. 
farinae) produce cysteine proteases and serine proteases (Donnelly et al. 2006), which are 
well known as ‘group 1 house dust mite allergens’ to induce allergic reactions. Several 
reports have shown that these proteases interact with pathways of the innate defense system 
suggesting that these might be also directly involved in inflammatory skin reactions. 
2.4 Neutrophil serine proteases  
Upon skin infection or at conditions causing ‘neutrophilic dermatoses’, the primary cell 
infiltrate consists of neutrophils. A massive infiltrate in the epidermis can lead to pustule 
formation. Upon infection, neutrophils phagocytose microbes and then kill these microbes 
within the phagolysosome by oxygen-radical-generating systems, the alpha-defensins as 
well as proteases which are released from primary (‘azurophilic’) as well as secundary 
(‘specific’) granules (Faurschou and Borregaard 2003). Only primary granules contain high 
amounts of the serine proteases human leukocyte elastase (HLE), cathepsin G and protease 
3 (PR3). These enzymes are not released upon phagocytosis. But upon ‘frustrating 
phagocytosis’ (attempts to phagocytose particles, which are bigger than leukocytes) as well 
as formation of “neutrophil extracellular traps” (NETs) consisting of neutrophil-derived 
DNA, where these cationic enzymes are bound (Brinkmann et al. 2004), a release of these 
enzymes can occur. Indeed, HLE activity is present at the surface of lesional skin of patients 
with psoriasis, a neutrophilic dermatosis (Wiedow et al. 1992). Neutrophil serine proteases 
have been identified as important innate immune regulators (Meyer-Hoffert 2009; Meyer-
Hoffert and Wiedow 2010). Thus, neutrophil-derived enzymes may further determine the 
outcome of an inflammatory skin lesion – independent of possible homeostasis of 
keratinocyte-derived proteases and protease-inhibitors. 
3. Protease inhibitors 
Proteolytic activity in the skin, which is often restricted to a few target proteins, its tissue 
localization and its enzymatic activity, needs to be properly controlled in the tissue. 
Although gene expression and zymogen-activation are important regulatory elements to 
restrict enzymatic activity, the most important one is the expression of more or less specific 
protease inhibitors within the skin. These inhibitors regulate more or less protease-
specifically in a timely and concentration-dependent fashion the activity of diverse 
proteases. This review will summarize the current knowledge on the most important 
epithelial protease-inhibitors. 
3.1 Kazal-type-realted protease inhibitors 
The ‘lympho-epithelial Kazal-type related inhibitor’ (LEKTI, today named LEKTI-1) is an 
effective inhibitor of multiple serine proteases (Roelandt et al. 2009). Processing of this 
multidomain protease inhibitor into fragments or single domains restricts the inhibitory 
properties to serine proteases such as trypsin, plasmin, subtilisin  A, cathepsin G and human 
neutrophil elastase. LEKTI-1 consists of 15 complete or incomplete Kazal domains. In vitro, 
recombinant LEKTI-1 fragments or single domains inhibit the keratinocyte-derived serine 
proteases KLK5, -6, -7, -13 and -14. LEKTI-1 is expressed in various stratified epithelia as three 
splice variants. In the epidermis LEKTI-1 is expressed in the stratum granulosum, where 
LEKTI-1 protein is located in lamellar bodies – separate from KLKs, but secreted into the 
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extracellular space together (Ishida-Yamamoto et al. 2004; Ishida-Yamamoto et al. 2005). The 
145 kDa form comprises all 15 potential inhibitory Kazal-domains, but it is cleaved rapidly 
into multidomain fragments, which might be cleaved further to produce single domains and 
complexes with KLK5 and KLK7 in the SC. These complexes dissociate at acidic pH, which 
due to a pH gradient within the SC may lead to a controlled homeostatic desquamation. 
Mutations in Spink5 (which encodes LEKTI-1) generating premature termination codons, as 
seen in Netherton Syndrome (Chavanas et al. 2000), result in expression of truncated LEKTI 
forms lacking several protease-inhibiting domains. This rare ichthyosiform skin disease is 
characterized by dry skin, increased desquamation, hair abnormalities (‘bamboo hair’) and 
atopy. A decreased level of functional LEKTI correlates inversely with serine protease activity 
in SC, a decrease physical barrier function and severity of the disease. 
Another Kazal-type inhibitor is LEKTI-2 (Spink9), which has been originally discovered in 
palmar and plantar SC extracts (Brattsand et al. 2009; Meyer-Hoffert et al. 2009). LEKTI-
2/SPINK9 is mainly expressed in palmar and plantar skin, close to KLK5. Apart from skin, 
expression was seen in the thymus (thus referred as LEKTI-2). All other tissues showed a 
very low transcription level of Spink9. LEKTI-2/SPINK9 selectively inhibited KLK5, but not 
other proteases including chymotryptic KLK7 and tryptic KLK14 or several serine proteases 
like trypsin and chymotrypsin. The LEKTI-2/SPINK9 activity differs in this respect from 
that of LEKTI-1: The Ki of LEKTI-2 was found in the range of 60 – 250 nM. LEKTI-1-domains 
have been reported to inhibit KLK5 in the range of 3 nM (domain 8-11) to 120 nM (domain 
9-15). Further, the LEKTI-1 domains exhibit a more or less broad activity spectrum. It 
remains to be determined whether LEKTI-2/SPINK9 plays a role in skin diseases. 
Considering the specific expression of LEKTI-2/SPINK9 at palmar and plantar sites as well 
as its specific activity to inhibit KLK5, it is intriguing to speculate that it could be a relevant 
factor in hand and foot eczema. 
By following the hypothesis that likely more Kazal-type inhibitors are present in human 
skin, we identified SPINK6 as a selective inhibitor of KLKs in the skin (Meyer-Hoffert et al. 
2010). Unlike LEKTI-1 but similar to LEKTI-2, SPINK6 possesses only one typical Kazal 
domain. SPINK6 is strongly expressed, unlike LEKTI-2, in skin from various locations and 
can be purified from human plantar SC extracts. At low levels it is expressed in many other 
tissues and is induced during keratinocyte differentiation. While immunohistochemical 
analyses revealed SPINK6 expression in the stratum granulosum of healthy human skin at 
various anatomical localizations and in the skin appendages, including sebaceous glands 
and sweat glands, SPINK6 expression was found to be decreased in lesions of atopic 
dermatitis. Recombinant SPINK6 inhibited KLK4, KLK5, KLK6, KLK7, KLK12, KLK13 and 
KLK14 but not KLK1, KLK3 and KLK11, suggesting a tissue KLK-selective inhibitory 
activity, since thrombin, trypsin, plasmin, matriptase, prostasin, mast cell chymase, 
cathepsin G, neutrophil elastase, and chymotrypsin were not inhibited (Meyer-Hoffert et al. 
2010; Kantyka et al. 2011). The finding that SPINK6 inhibited desquamation of human 
plantar callus in an ex vivo model suggests that SPINK6 plays a role in modulating the 
activity of KLKs in human skin. Interestingly, SPINK6 exhibited some proteolytic inhibitory 
activity against caspase-14 and is so far the only reversible inhibitor of caspase-14 in human 
skin (Kantyka et al. 2011).  
3.2 Trappins and serpins of human skin 
Apart from LEKTIs keratinocytes produce a number of additional protease inhibitors. 
Members of one group are termed ‘trappins’ (acronym for transglutaminase substrate, 
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WAP-domain-containing proteins) (Schalkwijk et al. 1999). Human epidermis contains two, 
secretory leukocyte protease inhibitor (SLPI) and elafin. Both are efficient inhibitors of 
neutrophil serine proteases: SLPI inhibits cathepsin G and elastase, elafin inhibits elastase 
and protease-3. This suggests that these protease inhibitors are important at inflammatory 
conditions to protect the tissue from damage caused by neutrophil serine proteases. 
Whereas SLPI is constitutively expressed in the epidermis, elafin is present at a low level in 
healthy skin, but highly up-regulated at inflammatory conditions such as psoriasis (Wiedow 
et al. 1990). Elafin is stored in lamellar bodies and thus secreted as precursor at the 
interphase between stratum granulosum and stratum corneum, where it is crosslinked to 
proteins of the CE via transglutamination.  
Another group of serine protease inhibitors are SERPINs, which encompass nearly 40 
members, of which many have been implicated in cancer and inflammation (Meyer-
Hoffert 2009). These protease inhibitors have a unique mechanism to inhibit enzymatic 
activity: SERPINs cause a conformational change of the protease and then covalently bind 
to it. A few members of the SERPIN family have been reported to be expressed in human 
skin, among them SERPINB3 (squamous cell carcinoma antigen-1), SERPINB4 (squamous 
cell carcinoma antigen-2), and SERPINB13 (headpin/hurpin). SERPINs have possibly a 
role in protecting tissue from proteolysis by bacterial proteases: SERPINB8 and SERPINB9 
are inhibiting subtilisin A. SERPINA1 inactivates some microbial proteases including 
protease K. Further, a C-terminal fragment of SERPINA1 inhibits HIV-1 entry by 
interaction with the gp41 fusion protein. 
3.3 Cystatins 
Apart from serine proteases also cysteine protease activity is under the control of inhibitors 
in skin: These include members of the cystatine gene family (Zeeuwen et al. 2009). Cystatins 
represent polypeptides which are members of a superfamily of evolutionarily-related 
proteins that can be divided in three subgroups, and which are widely expressed in several 
human tissues and secretions. They effectively inhibit various cysteine proteases, such as 
cathepsins B, L, H, K, and S, at micromolar to picomolar concentration in a competitive and 
reversible manner. Whereas cystatin A and cystatin C were reported to act as epidermal 
protease inhibitor with antimicrobial properties – possibly by inhibiting microbial cysteine 
proteases -  cystatin M/E regulates in the epidermis crosslinking of structural proteins by 
transglutaminase 3 in the cornification process by controlling cathepsin L and legumain 
activities (Meyer-Hoffert 2009). Cathepsin L has been shown to activate transglutaminase 3, 
an epidermis-specific enzyme that is important in the cornification process where it is 
responsible for crosslinking of small proline-rich proteins and loricrin. A deregulation of 
this pathway by uncontrolled cysteine protease activity leads to abnormal stratum corneum 
and disturbance of skin barrier function (Zeeuwen et al. 2009). 
3.4 Other regulating factors of protease activity  
It should not be overlooked that the proteolytic activity of proteinases depends on factors 
like pH and ion-concentration. All serine proteases including KLKs decrease their 
proteolytic activity in acidic environments. The physiological pH of around 5.5 already 
results in more than 90% less active compared to optimal in vitro conditions. Patients with 
atopic dermatitis often show an elevated pH at the skin surface, which might likely 
contribute to observed elevated serine protease levels in these patients (Voegeli et al. 2009). 
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Interestingly, the inhibitory of activity of LEKTI-1 depends on the pH, too, which might 
enhance proteolytic deregulation, when the epidermal pH is elevated. Moreover, Zn2+ 
inhibits KLK5 (Debela et al. 2007). This might have clinical consequences, when Zink levels 
are low as in acrodermatits enteropathica. The exfoliation and inflammation observed in this 
disease might be a result of decreased KLK5 inhibitions. 
4. Protease-activated receptors (PARs)  
PARs represent seven membrane-spanning G-protein coupled receptors, which are 
activated by serine proteases, which cleave a ‘tethered’ receptor-activating ligand at the N-
terminus (Steinhoff et al. 2005). To date, four PARs (PAR1-4) have been characterized. PAR-
1, PAR-3 and PAR-4 are activated by thrombine, and PAR-2 by trypsin and chymotrypsin. 
In human skin, PAR-2 is abundantly expressed by keratinocytes (Steinhoff et al. 1999), 
where it plays a role in regulating permeability barrier homeostasis, inflammation, pruritus, 
pigmentation, and wound healing upon activation by various endogenous and exogenous 
serine proteases. Whereas during skin-inflammation, PAR-2 is activated by neutrophil 
elastase and mast cell tryptase, upon infection or skin barrier defects proteases originating 
from certain bacteria, house dust mites, cockroaches or parasites can activate this receptor 
(Shpacovitch et al. 2007). Activation by Propionibacterium acnes protease causes induction of 
certain proinflammatory proteins, matrix metalloproteinases and antimicrobial peptides, 
including hCAP18/LL-37 (Lee et al. 2010). 
5. Epidermal serine proteases and their inhibitors in atopic dermatitis 
Our understanding of the pathogenesis of Atopic Dermatitis has increased by the discovery 
of pro-filaggrin (FLG) mutations as the major predisposing factor of AD and the 
genodermatose Netherthon Syndrom, which shows similarities to AD.  FLG mutations lead 
to decreased or missing filaggrin, which leads to dry skin as its cleavage and processing 
product, the skin moisturizing factor, is decreased. The skin barrier defect leads to increases 
antigen penetration, which finally leads to specific sensitization and allergic inflammation. 
Here we have learnt from the ND model that missing LEKT-1 leads to increased KLK 
activity, which activate PAR-2, thus resulting in increased thymic stromal lymphopoetin 
(TSLP) (Briot et al. 2009). TSLP finally leads to a Th2 imbalance. Therefore, both events, the 
Filaggrin defect and the KLK-PAR2-TSLP axis, seem to be crucial for inducing AD. 
To date, there is no evident point demonstrating that either intrinsic or extrinsic signals are 
promoting cutaneous allergic-type inflammation in AD. The fact that only 37–50% of 
patients with Ichthyosis vulgaris develop atopic manifestations (Kuokkanen 1969; Smith et al. 
2006), supports the notion that in NS in which all patients develop allergic manifestations, 
additional mechanisms to primary skin barrier defect have a key role in immune response 
polarization toward a Th2 response. Since serine protease activity is elevated in AD patients 
(Voegeli et al. 2009), one might speculate that similar mechanisms are involved in AD as in 
ND. It was reported recently that KLK11 and KLK7 are elevated in lesions of AD patients 
(Voegeli et al. 2011). Some genetic studies have suggested that proteases and inhibitors are 
involved in the genetic predisposition of AD patients.  In a case–control study on 103 AD 
patients and 261 matched controls, a significant association was found between a 4-bp 
insertion in the 3′-untranslated region of the KLK7 gene, encoding KLK7 and AD 
(Vasilopoulos et al. 2004)). This association of the 4-bp insertion mutation with AD could not 
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be confirmed in two independent studies (Hubiche et al. 2007; Weidinger et al. 2008). 
SPINK5 gene mutations are linked the with AD, when maternally inherited (Walley et al. 
2001; Kato et al. 2003; Nishio et al. 2003; Weidinger et al. 2008). It is worth noting that the 
association was weaker than in the case of FLG mutations, in part, owing to a high 
prevalence in the control population. In a separate study on a French population, an 
association between SPINK5 and AD was not found; however, there was an association 
between carriers and raised IgE serum levels (Hubiche et al. 2007)). The association of 
SPINK5 mutations with raised IgE serum levels and with other atopic conditions, such as 
asthma, led to the suggestion that they are risk factors for general atopy (Walley et al. 
2001; Nishio et al. 2003). In addition to SPINK5, a mutation has been identified in the 
CSTA gene encoding the cysteine protease inhibitor, cystatin A, which associates with 
AD. The cystatin A gene maps to chromosome 3q21, which has been identified as a major 
susceptibility locus for AD (Lee et al. 2000).  
6. Conclusion 
Until today the complex pathogenesis of AD is not fully understood. But there is more 
and more evidence that epidermal proteases and their inhibitors are involved in the 
pathogenesis of AD. Their expression can be altered by genetic mutations and their 
activity is influenced by environmental factors like the pH, which is increased in AD 
patients (Sparavigna et al. 1999). Taken together there seems to exist a feedback regulation 
system important for skin barrier homeostasis in AD especially for kallikrein activity 
involving filaggrin mutations, PAR2 and LEKTI expression Tanaka 2011. It will be 
interesting to see whether inhibition of elevated protease activity will improve severity of 
AD lesions. Clinical trials are currently on their way with promising preliminary results 
(http://clinicaltrial.gov). 
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